Income Statement
ARMATA PHARMACEUTICALS, INC.
ARMP
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Expenses
|
41.54 | 47.61 | 45.42 | 42.45 | 28.30 | 22.41 | 19.75 | 12.52 | 16.27 | 23.64 | 10.70 | 14.52 |
|
Research & Development
|
23.72 | 34.43 | 33.77 | 35.02 | 20.02 | 14.44 | 9.82 | 4.89 | 2.88 | 5.68 | 3.99 | 5.81 |
|
Selling, General & Administrative
|
12.41 | 13.18 | 11.65 | 7.44 | 8.28 | 7.97 | 9.27 | 5.70 | 7.59 | 8.41 | 6.42 | 6.85 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-41.54 | -47.61 | -45.42 | -42.45 | -28.30 | -22.41 | -19.75 | -12.52 | -16.27 | -23.64 | -10.70 | -14.52 |
|
Non-Operating Income
|
- | - | - | - | - | - | -0.27 | -0.09 | -2.13 | -4.24 | -10.11 | - |
|
Interest Income
|
- | - | 0.18 | 0.03 | 0.01 | 0.03 | 0.10 | - | - | - | - | - |
|
Interest Expense
|
- | 6.70 | 2.63 | 0.00 | 0.10 | 0.63 | 0.93 | - | - | - | - | 0.00 |
|
Other Non-Op Income / Expense
|
-137.17 | 23.52 | -28.16 | 0.03 | 0.67 | -0.59 | 0.27 | 0.09 | 2.02 | 3.98 | 9.64 | - |
|
Income Before Tax
|
-173.80 | -18.92 | -0.07 | -36.92 | -23.16 | -22.18 | -19.48 | -12.44 | -14.14 | -19.39 | -0.59 | - |
|
Income Tax Expense
|
- | - | - | - | - | - | 0.00 | -0.33 | -1.30 | -0.56 | -0.07 | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-173.80 | -18.92 | -69.05 | -36.92 | -23.16 | -22.18 | -19.48 | -12.11 | -12.84 | -18.84 | -0.52 | 0.00 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-41.54 | -46.29 | -44.45 | -42.45 | -28.30 | -22.41 | -19.75 | -12.52 | -16.27 | -23.64 | -10.70 | -14.52 |
|
Earnings Per Share (Basic)
|
-4.80 | -0.52 | -1.91 | -1.08 | -0.96 | -1.35 | -2.49 | -0.64 | -2.01 | - | -1.99 | 0.12 |
|
Diluted EPS
|
-4.80 | -0.89 | -1.91 | -1.08 | -0.96 | -1.35 | -2.55 | -0.64 | -2.18 | - | -1.99 | 0.07 |
|
Weighted Average Shares
|
36.24 | 36.16 | 36.08 | 34.29 | 24.10 | 16.42 | 7.83 | 18.98 | 6.39 | - | 5.41 | 187.33 |
|
Diluted Weighted Avg Shares
|
36.24 | 59.06 | 36.08 | 34.29 | 24.10 | 16.42 | 8.01 | 19.06 | 6.57 | - | 5.41 | 323.60 |
|
Comprehensive Income
|
- | - | - | - | - | - | - | - | - | - | - | - |